🇺🇸 ASTRAZENECA PLCAZN

Company Update Form 6-K 16-11-2026 07:13:23 EST

Subject: 6-K — Foreign issuer report

Overview: FDA approved Imfinzi in combination with enfortumab vedotin for muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy, following VOLGA Phase III trial results.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest